Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tarsa's $28M to give oral calcitonin another chance, following 2011 Novartis failure

This article was originally published in Scrip

Executive Summary

Tarsa Therapeutics, a small private US company, has raised the $28 million it needed to seek FDA approval (and following that, European approval) of its first drug – an oral recombinant salmon calcitonin, Ostora, for the treatment of postmenopausal osteoporosis, a multi-billion-dollar market. The withdrawal in November 2011 of a Phase III competitor oral formulation from Novartis clears the market for Tarsa.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016669

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel